Targeting cardiovascular and metabolic risk modification in end stage renal disease (ESRD): a randomized controlled clinical trial on niacin's effects on lipoprotein(a) and biochemical markers in hemodialysis patients.

The same observation occurred in potassium level, where controlled patients gained a significant hyperkalemia, which increased by 23.9% from baseline, while there was a substantial decrease in potassium level in the niacin group by 27%, so there was a highly significant reduction between both groups in favor of the niacin group ( p -value 0.001).

also in 132,142 other papers